1. Topiramate for the Treatment of Binge Eating Disorder Associated With Obesity: A Placebo-Controlled Study 
Susan L. McElroy, James I. Hudson, Julie A. Capece, Karen Beyers, Alan C. Fisher, Norman R. Rosenthal 
Biological Psychiatry 
Volume 61, Issue 9, Pages (May 2007)
DOI: /j.biopsych
Copyright © 2007 Society of Biological Psychiatry Terms and Conditions

2. Figure 1
Population Flow Diagram. *Safety: all randomized patients for whom at least one post-baseline safety measure was available. †ITT: all randomized patients who received study medication and had at least one valid post-baseline efficacy evaluation. ‡mITT: all ITT patients excluding those with ≥ 1 major inclusion/exclusion violation (no diagnosis of binge eating disorder [BED]; did not have ≥ 3 binge days/week at baseline; had baseline body mass index [BMI] < 30 kg/m2; or Montgomery-Åsberg Depression Rating Scale [MADRS] > 24). §Completers: all randomized patients who completed all study visits up to and including visit 10 and exceeded 99 days of taking study medication.
Biological Psychiatry  , DOI: ( /j.biopsych )
Copyright © 2007 Society of Biological Psychiatry Terms and Conditions

3. Figure 2 The mean number of binge eating days/week.
Biological Psychiatry  , DOI: ( /j.biopsych )
Copyright © 2007 Society of Biological Psychiatry Terms and Conditions

4. Figure 3 The median number of binge eating days/week.
Biological Psychiatry  , DOI: ( /j.biopsych )
Copyright © 2007 Society of Biological Psychiatry Terms and Conditions

5. Figure 4 The mean number of binge eating episodes/week.
Biological Psychiatry  , DOI: ( /j.biopsych )
Copyright © 2007 Society of Biological Psychiatry Terms and Conditions

6. Figure 5
Body mass index.
Biological Psychiatry  , DOI: ( /j.biopsych )
Copyright © 2007 Society of Biological Psychiatry Terms and Conditions